Nuvation Bio (NUVB) to Release Earnings on Thursday

Key Points

• Nuvation Bio is set to announce its Q2 2025 earnings on Thursday, August 7th, with analysts expecting a loss of ($0.17) per share and revenue of $0.42 million.
• Insider Dongfang Liu recently sold 20,000 shares of Nuvation Bio, representing a 62.50% decrease in their position.
• Analysts have given Nuvation Bio a consensus rating of "Buy" with an average price target of $7.17, following recent upgrades from various firms.

Nuvation Bio (NYSE:NUVB - Get Free Report) will likely be issuing its Q2 2025 quarterly earnings data before the market opens on Thursday, August 7th. Analysts expect the company to announce earnings of ($0.17) per share and revenue of $0.42 million for the quarter.

Nuvation Bio (NYSE:NUVB - Get Free Report) last issued its earnings results on Wednesday, May 7th. The company reported ($0.16) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.16). Nuvation Bio had a negative return on equity of 44.14% and a negative net margin of 5,534.21%. The company had revenue of $3.08 million during the quarter, compared to analysts' expectations of $0.42 million. On average, analysts expect Nuvation Bio to post $0 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Nuvation Bio Stock Performance

Shares of NYSE NUVB traded down $0.14 during trading on Friday, hitting $2.22. 3,600,421 shares of the company were exchanged, compared to its average volume of 4,895,160. The company has a fifty day moving average price of $2.19 and a 200-day moving average price of $2.15. The firm has a market capitalization of $755.38 million, a PE ratio of -0.94 and a beta of 1.35. Nuvation Bio has a 12-month low of $1.54 and a 12-month high of $3.45.

Analyst Ratings Changes

Several research firms have weighed in on NUVB. Citigroup began coverage on shares of Nuvation Bio in a report on Wednesday, April 23rd. They issued an "outperform" rating on the stock. Royal Bank Of Canada raised shares of Nuvation Bio from an "outperform" rating to a "moderate buy" rating and reduced their price target for the company from $10.00 to $6.00 in a research report on Tuesday, June 17th. Wall Street Zen upgraded Nuvation Bio from a "sell" rating to a "hold" rating in a research report on Saturday, July 26th. JMP Securities restated a "market outperform" rating and issued a $6.00 target price on shares of Nuvation Bio in a research report on Wednesday, June 25th. Finally, Citizens Jmp initiated coverage on Nuvation Bio in a research note on Wednesday, April 23rd. They issued a "mkt outperform" rating and a $6.00 price target on the stock. One equities research analyst has rated the stock with a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Buy" and an average price target of $7.17.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in shares of Nuvation Bio by 4.4% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 108,547 shares of the company's stock valued at $191,000 after buying an additional 4,608 shares during the period. Millennium Management LLC grew its position in Nuvation Bio by 52.4% in the 1st quarter. Millennium Management LLC now owns 3,774,003 shares of the company's stock valued at $6,642,000 after acquiring an additional 1,298,131 shares in the last quarter. Finally, Envestnet Asset Management Inc. acquired a new position in Nuvation Bio in the 2nd quarter valued at about $92,000. 61.67% of the stock is currently owned by institutional investors and hedge funds.

About Nuvation Bio

Nuvation Bio Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-868, a BD2 selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation, including oncogenes comprising c-myc; NUV-1156, an AR binder Xtandi that address advanced stage prostate cancers with the potential to move into earlier lines typically treated with surgical prostatectomy; and drug-drug conjugate (DDC) platform which leverages a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies to deliver anti-cancer therapeutics to cancer cells, as well as NUV-1176, a PARP inhibitor to address ER+ breast and ovarian cancer.